Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 640-646

  Buti, Maria ^a   Brosa, Max ^b   Casado, Miguel A ^c   Rueda, Magdalena ^d   Esteban, Rafael ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Oblikue Consulting   (Spain)

^c Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^d GILEAD SCIENCES   (United States)

Author keywords

Chronic hepatitis B; Cost effectiveness analysis; Oral antiviral therapy

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIFE EXPECTANCY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT RESPONSE;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; PHOSPHONIC ACIDS; QUALITY-ADJUSTED LIFE YEARS;

EID: 69949132951     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.04.013     Document Type: Article

References (33)

1. Ganem D., and Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
2. Lok A.S.F., and McMahon B.J. Chronic hepatitis B; AASLD practice guidelines. Hepatology 45 (2007) 507-539
3. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S.F. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
4. Brown R., Cock E., Colin X., Antoñanzas F., and Iloeje U. Hepatitis B management costs in France, Italy, Spain and the United Kingdom. J Clin Gastroenterol 38 (2004) S169-S174
5. Idris B.I., Brosa M., Richardus J.H., Esteban R., Schalmb S.W., and Buti M. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol 20 (2008) 320-326
6. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
7. Mommeja-Marin H., Mondou E., Blum M.R., and Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37 (2003) 1309-1319
8. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
9. EASL Guidelines European Association for the Study of the Liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
10. Marcellin P., Heathcote E.J., Buti M., Gane E., DeMan R., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359 (2008) 2442-2455
11. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
12. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
13. Peters M.G., Hann H.W., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
14. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
15. Liaw Y.F., Leung N., Guan R., Lau G.K.K., Merican I., McCaughan G., et al. For the Asian Pacific consensus update working party of chronic hepatitis B. Liver Int 25 (2005) 472-489
16. Lampertico P., Viganò M., Manenti E., Iavarone M., Sablon E., and Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
17. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
18. Liaw Y.F., Gane E., Leung N., Zeuzem S., Wang Y., Lai C.L., et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136 (2009) 486-495
19. Marcellin P., Buti M., Kratev Z., Gural S., Balabanska R.I., Dusheiko G., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (Study 102), preliminary analysis. Hepatology 48 (2008) 370A
20. Heathcote E., Gane E.J., de Man R.A., Chang S., Sievert W., Mauss S., et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis. Hepatology 48 suppl (2008) 376A
21. Van Bommel F., Zollner B., Sarrazin C., Spengler U., Huppe D., Moller B., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44 (2006) 318-325
22. Van Bömmel F., Wunsche T., Mauss S., Reinke P., Bergk A., Schurmann D., et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40 (2004) 1421-1425
23. Van Bömmel F., de Man R.A., Stein K., Hüuppe D., Petersen J., Buggisch P., et al. A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience. J Hepatol 48 (2008) S32
24. Snow-Lampart A., Chappell B.J., Curtis M., Zhu Y., Heathcote E., Marcellin P., et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg QD. Hepatology 48 (2008) 745A
25. Han B., Chang T.T., Chao Y.T., Yoon S.K., Gish R.G., Cheinquer H., et al. Five years of continuous entecavir for nucleoside-nai{dotless}̈ve HBeAg (+) chronic hepatitis B: results from Study ETV-901. Hepatology 48 (2008) 705A
26. Van Bömmel F., Feucht H., Schlosser B., Weich V., Schott E., Wiedenmann B., et al. Detection of mutations associated with resistance to nucleos(t)ide analogs in patients with HBV infection during treatment with tenofovir. Hepatology 48 (2008) 715A
27. López Bastida J, Oliva J, Antoñanzas F, Garci{dotless}́a-Altés A, Gisbert R, Mar J, et al. Propuesta de gui{dotless}́a para la evaluación económica aplicada a las tecnologi{dotless}́as sanitarias. Madrid: Plan Nacional para el SNS del MSC. Servicio de Evaluación del Servicio Canario de la Salud; 2008. Informes de Evaluación de Tecnologi{dotless}́as Sanitarias: SESCS No. 2006/22. Available from: http://aunets.isciii.es/ficherosproductos/132/MemoriaFinal.pdf.
28. Herdman M, Ossa D, Briggs A, Casanovas T, Garci{dotless}́a-Samaniego J, Fusté LC, et al. Measuring preferences for health states resulting from chronic hepatits B infection in a Spanish population. In: 12th international symposium on viral hepatitis and liver disease. Paris, July 1-5; 2006.
29. Claxton K., Schupher M., McCabe C., Briggs A., Akehurst R., Buxton M., et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 14 (2005) 339-347
30. Sun X., Qin W.X., Li Y.P., and Jiang X.H. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. J Gastroenterol Hepatol 22 (2007) 1369-1377
31. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., and Spiegel B.M. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 142 (2005) 821-831
32. Buti M., Casado M.A., Calleja J.L., Salmerón J., Aguilar J., Rueda M., et al. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 23 (2006) 409-419
33. Veenstra D.L., Sullivan S.D., Clarke L., Iloeje U.H., Tafesse E., Di Bisceglie A., et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 25 (2007) 963-977